CRESCENT BIOPHARMA, INC.
About CRESCENT BIOPHARMA, INC.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $10.8M
- Net income
- -$153.9M
- Total assets
- $240.3M
- Market cap
- $496.3M
- Operating margin
- -1407.5%
- Net margin
- -1419.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $10.8M
- Operating expenses
- $163.5M
- Operating income
- -$152.6M
- Income tax
- $2.0M
- Net income
- -$153.9M
Balance sheet
- Total assets
- $240.3M
- Current assets
- $236.7M
- Total liabilities
- $37.3M
- Current liabilities
- $36.1M
- Shareholders’ equity
- $203.0M
Cash flow
- Operating cash flow
- -$71.5M
- Investing cash flow
- -$72.9M
- Financing cash flow
- $323.0M
- Net cash flow
- $178.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $496.3M
- Shares outstanding
- 28.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 16, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $153.9M in FY2025.
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CRESCENT BIOPHARMA, INC..
Write a review
News about CRESCENT BIOPHARMA, INC.
News & sentiment via Polygon.io
